69: Liver Transplantation

Published on 06/02/2015 by admin

Filed under Anesthesiology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1311 times

CHAPTER 69 Liver Transplantation

2 Describe some indications and contraindications for liver transplantation

Indications for liver transplantation include end-stage liver disease from hepatocellular disease, cholestatic disease, vascular disease, or polycystic disease. In addition, some nonresectable hepatic malignancies, metabolic liver diseases, and fulminant hepatic failure are indications (Table 69-1). Over time relative and absolute contraindications for liver transplantation have evolved (Table 69-2). Because MELD predicts 3-month survival, those with the highest scores have the greatest chance of dying from liver disease and thus have the best risk-benefit ratio for undergoing liver transplantation.

TABLE 69-1 Indications for Liver Transplantation

TABLE 69-2 Contraindications to Liver Transplantation

AIDS, Acquired immunodeficiency syndrome; HIV, human immunodeficiency virus.

Modified from Maddrey WC, Van Thiel DH: Liver transplantation: an overview, Hepatology 8:948, 1988.

4 What are some preanesthetic considerations in a liver transplant patient?

Optimal anesthetic management of these complex, critically ill patients requires management of the pathophysiologic changes of liver disease, comorbid conditions, and the physiologic changes associated with the surgery. In some instances (e.g., pulmonary hypertension, hepatorenal syndrome), hepatic disease may be overshadowed by the severity of the comorbid conditions. Prior abdominal surgeries and encephalopathy are important features to note, as are coagulation deficits (factor deficiencies and thrombocytopenia). The thromboelastogram (TEG) provides valuable insight into the patient’s entire clotting process. The TEG graphs the viscoelastic properties of a clot from the formation of the first fibrin strands to the full hemostatic plug. Thus the TEG is a dynamic test showing the evolution of clot formation. Because the TEG examines multiple phases of clot formation within a single test, it reflects information that is otherwise available only in multiple tests. The TEG is the best laboratory assessment of qualitative platelet function.

Electrolyte abnormalities are common. Hypokalemia is commonly seen in earlier stages of liver disease since hepatic injury leads to hyperaldosteronism. Hyperkalemia may be caused by the use of potassium-sparing diuretics to treat ascites and hepatorenal syndrome. Hyponatremia may result from diuretic use, hyperaldosteronism, or volume overload. Renal dysfunction should be assessed since intraoperative dialysis may be necessary. In fulminant hepatic failure, cerebral cytotoxic edema is a common complication, and there must be aggressive preoperative control of intracranial pressure to prevent brainstem herniation, a common cause of death. Patients with cerebral edema should have an intracranial pressure monitoring device.

Pulmonary hypertension associated with cirrhosis occurs in approximately 8% of patients and is a cause of significant intraoperative morbidity and mortality. Many liver failure patients are hypoxemic secondary to atelectasis and hepatopulmonary syndrome. All potential transplant candidates should undergo a screening transthoracic echocardiogram to assess pulmonary arterial pressures, left ventricular function, and intrapulmonary shunting. If pulmonary arterial pressures are elevated or right ventricular function is decreased, a right heart catheterization may be indicated.

5 What is the significance of portal pulmonary hypertension? How are these patients managed in the pretransplant period?

In contrast to most transplant recipients, portal pulmonary hypertension (PPHTN) patients have an increased risk of death because of right ventricular failure in the peritransplantation period. Physicians are uncertain which PPHTN patients may undergo transplantation because there are no patient characteristics that clearly predict outcome. Patients with moderate to severe PPHTN should not be considered candidates until they undergo a trial of vasodilator therapy. The cause of pulmonary hypertension in liver failure patients is unknown, but the disease shares many similarities with primary pulmonary hypertension. Tissue hypoxia likely plays a role. The pulmonary circulation has increased vascular resistance that is transmitted back to the right heart and liver. The pulmonary vessels of patients with PPHTN are unable to accommodate increased blood flow during periods of aggressive blood transfusion and during the hyperdynamic postreperfusion phase, potentially resulting in acute right ventricular failure. Rapid dilation of the right ventricle can also compress the right coronary vessels, producing myocardial ischemia and infarction. Pulmonary hypertension will not resolve in all patients who were successfully transplanted with a new liver.

Vasodilators reduce pulmonary artery pressures and prolong survival in some pulmonary hypertension patients. The prostaglandin epoprostenol (Flolan) can reduce pulmonary artery pressures when given as a chronic infusion and has been used to bridge patients to transplantation. Nitric oxide inhaled in doses up to 80 ppm also acutely reduces pulmonary artery pressures in a small number of PPHTN patients and has been used in the operating room to reduce pulmonary artery pressures. More recently, sildenafil (Revatio) has been implemented as an oral agent to reduce pulmonary hypertension in transplant candidates.

6 What are the concerns before anesthetic induction in the patient with end-stage liver disease?

9 List some of the anesthetic concerns during the preanhepatic (dissection) phase

10 What are some anesthetic concerns that arise during stage 2, the anhepatic phase?

Once the dissection is finished, blood loss is usually minimal, but blood volume may be decreased from hemorrhage during the preanhepatic phase. Because the inferior vena cava is typically cross-clamped, half of the patient’s blood volume is confined to the lower body. Therefore central filling pressures are a poor representation of total body blood volume. Most therapy in this phase is directed toward achieving hemodynamic stability and preparing for reperfusion by correcting potassium and pH. Steroids are also administered during this stage. Steroids are the initial step in rendering the patient immunosuppressed so he or she will not reject the new organ. They must be administered before reperfusion.

Hyperkalemia, hypocalcemia, and metabolic acidosis are common during the anhepatic stage and must be corrected since the anhepatic patient has no means of physiologic compensation. Hypernatremia caused by administration of sodium bicarbonate for metabolic acidosis is managed by administration of dextrose in water (D5W). Increases in PaCO2 associated with bicarbonate administration also require adjustments in ventilation. Perhaps a better buffering agent is tromethamine (THAM). THAM is a low sodium buffer that does not increase sodium or PaCO2. As previously discussed, serum potassium must be aggressively lowered to <3.5 mEq/L to prevent hyperkalemia-induced asystole during reperfusion. Hyperventilation, alkalinizing agents, and insulin are all effective at doing this. The severity of these electrolyte abnormalities is related to the length of stage 2, severity of patient illness, hypotension, number of blood products administered, and renal function.

An acute decrease in venous return following caval occlusion leads to hypotension. There is relative hyperemia inferior to the cross-clamp and poor venous return above the cross-clamp. Distal anatomic shunts may act as capacitance vessels, sequestering intravascular volume and regulating rates of venous return. New vessel formation, in addition to enlargement of portosystemic connections, will influence central venous return and therefore cardiac output following caval occlusion. Although there are no reliable predictors of hemodynamic instability during venous occlusion, an accentuated hyperdynamic circulatory state, severe portal hypertension, and advanced age have been associated with adverse hemodynamic events.

11 Define reperfusion syndrome. What are its clinical implications?

Reperfusion syndrome is characterized by either a decrease of 30% or more in mean arterial pressure (from baseline) for greater than 1 minute and occurring within the first 5 minutes of reperfusion or a mean arterial pressure less than 60 mm Hg under the same circumstances. Following portal vein unclamping, approximately 30% of patients will exhibit profound cardiovascular collapse on reperfusion irrespective of attentive management during stage 2. This tends to be more profound with a histidine, tryptophan, ketoglutarate preservative solution as opposed to a University of Wisconsin preservative solution. The bradycardia, myocardial depression, and systemic vasodilation noted during reperfusion are secondary to rapid increases in serum potassium, decreases in temperature, acute acidosis, and release of vasoactive substances by the grafted liver. These vasoactive mediators include prostaglandins, kallikrein, platelet-activating factor, and leukotrienes. Increased age and larger donor organs also are considered risk factors.

Generally treatment with calcium, atropine, and/or epinephrine improves cardiovascular function. Fluid administration should be judicious because it can aggravate the already increased filling pressures (secondary to myocardial depression), resulting in impaired hepatic perfusion. Although the hemodynamic changes generally subside within 10 to 15 minutes, pulmonary hypertension, elevated central venous pressure, and hypotension may persist. Continuous vasopressors such as vasopressin or phenylephrine may be necessary to combat the persistent vasodilation.

12 Describe some of the major anesthetic management issues during the reperfusion stage (stage 3)